We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

53 hedge funds and large institutions have $756M invested in BridgeBio Oncology in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

26% more funds holding

Funds holding: 42 → 53 (+11)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

15% more capital invested

Capital invested by funds: $658M → $756M (+$98.6M)

1.16% more ownership

Funds ownership: 71.74% → 72.9% (+1.2%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
0.64%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
15
Increased
12
Reduced
12
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.12M
2
LCM
Laurion Capital Management
New York
+$5.08M
3
CCM
Catalio Capital Management
New York
+$4.98M
4
PBA
Paradigm Biocapital Advisors
New York
+$4.79M
5
HS
HighVista Strategies
Massachusetts
+$2.78M

Top Sellers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
-$5.3M
2
ACM
ADAR1 Capital Management
Texas
-$3.33M
3
Millennium Management
Millennium Management
New York
-$1.55M
4
SC
Stempoint Capital
New York
-$1.21M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
26
HighVista Strategies
Massachusetts
$2.87M +$2.78M +229,263 New
ACM
27
ADAR1 Capital Management
Texas
$2.83M -$3.33M -274,980 -55%
IC
28
Ikarian Capital
Texas
$2.76M -$303K -25,000 -10%
State Street
29
State Street
Massachusetts
$2.73M +$504K +41,583 +24%
SCM
30
Sio Capital Management
New York
$1.64M – – –
TD Asset Management
31
TD Asset Management
Ontario, Canada
$1.47M -$156K -12,912 -10%
WP
32
Woodline Partners
California
$1.3M – – –
MCM
33
Moore Capital Management
New York
$1.25M – – –
Goldman Sachs
34
Goldman Sachs
New York
$1.19M +$1.15M +94,651 New
UBS Group
35
UBS Group
Switzerland
$1.17M +$499K +41,143 +79%
SC
36
Stempoint Capital
New York
$1.08M -$1.21M -100,097 -54%
Renaissance Technologies
37
Renaissance Technologies
New York
$930K +$900K +74,300 New
BFM
38
Boothbay Fund Management
New York
$839K -$358K -29,517 -31%
Northern Trust
39
Northern Trust
Illinois
$727K -$460K -37,923 -40%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$670K +$657K +54,192 New
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$450K +$436K +35,952 New
XT
42
XTX Topco
Cayman Islands
$358K +$63.6K +5,249 +22%
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$331K +$321K +26,472 New
BC
44
BIT Capital
Germany
$313K +$303K +25,000 New
Point72 Asset Management
45
Point72 Asset Management
Connecticut
$295K +$286K +23,584 New
Morgan Stanley
46
Morgan Stanley
New York
$180K +$163K +13,491 +1,567%
QC
47
Quadrature Capital
United Kingdom
$162K +$157K +12,922 New
Squarepoint
48
Squarepoint
New York
$144K +$140K +11,515 New
PAP
49
Persistent Asset Partners
Hong Kong
$107K +$104K +8,585 New
CIBC Private Wealth Group
50
CIBC Private Wealth Group
Georgia
$62.6K +$60.6K +5,000 New
1
2
3

BBOT Hedge Fund Activity: Q4 2025 in Review

53 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2025, worth a combined $756M — up 15% from $658M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BBOT positions and 4 closed out — a net gain of 11 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Armistice Capital, adding an estimated $7.12M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $5.3M sold.

  • 53 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2025, up from 42 in Q3 2025.
  • Funds reported $756M of BridgeBio Oncology stock for Q4 2025, up 15% quarter-over-quarter.
  • 15 funds opened new BridgeBio Oncology positions in Q4 2025 and 4 closed out, a net change of +11 holders.
  • The largest BridgeBio Oncology buyer in Q4 2025 was Armistice Capital, an estimated $7.12M added.
  • The largest BridgeBio Oncology seller in Q4 2025 was Silverarc Capital Management, an estimated $5.3M sold.

Based on aggregated 13F filings for Q4 2025.